ΠΠΎΡΠ΅ΡΠ½Π°ALMKT β’ EPA
add
Mauna Kea Technologies SA
ΠΡΠ΅ΡΡ
ΠΎΠ΄Π½ΠΎ Π·Π°ΠΊΡΡΡΠ΅Π½ΠΎ
0,18Β β¬
ΠΠ½Π΅Π²Π½ΠΈ ΠΎΠΏΡΠ΅Π³
0,18Β β¬ - 0,19Β β¬
ΠΠΎΠ΄ΠΈΡΡΠΈ ΠΎΠΏΡΠ΅Π³
0,069Β β¬ - 0,23Β β¬
Π’ΡΠΆΠΈΡΠ½Π° Π²ΡΠ΅Π΄Π½ΠΎΡΡ
33,68Β ΠΌΠΈΠ». EUR
ΠΡΠΎΡΠ΅ΡΠ½Π° ΠΊΠΎΠ»ΠΈΡΠΈΠ½Π°
2,19Β ΠΌΠΈΠ».
Π¦Π΅Π½Π°/Π·Π°Ρ.
-
ΠΠΎΠ±ΠΈΡ ΠΎΠ΄ Π΄ΠΈΠ²ΠΈΠ΄Π΅Π½Π΄ΠΈ
-
ΠΡΠΈΠΌΠ°ΡΠ½Π° ΡΠ°Π·ΠΌΠ΅Π½Π°
EPA
ΠΠ΅ΡΡΠΈ ΡΠ° ΡΡΠΆΠΈΡΡΠ°
Π€ΠΈΠ½Π°Π½ΡΠΈΡΠ΅
ΠΠΈΠ»Π°Π½Ρ ΡΡΠΏΠ΅Ρ
Π°
ΠΡΠΈΡ
ΠΎΠ΄
ΠΠ΅ΡΠΎ ΠΏΡΠΈΡ
ΠΎΠ΄
| (EUR) | ΡΡΠ½ 2025.info | ΠΡΠΎΠΌΠ΅Π½Π° Π/Π |
|---|---|---|
ΠΡΠΈΡ
ΠΎΠ΄ | 2,02Β ΠΌΠΈΠ». | -5,58% |
Π’ΡΠΎΡΠΊΠΎΠ²ΠΈ ΠΏΠΎΡΠ»ΠΎΠ²Π°ΡΠ° | 3,02Β ΠΌΠΈΠ». | -13,98% |
ΠΠ΅ΡΠΎ ΠΏΡΠΈΡ
ΠΎΠ΄ | -2,33Β ΠΌΠΈΠ». | 0,36% |
ΠΠ΅ΡΠΎ ΠΏΡΠΎΡΠΈΡΠ°Π±ΠΈΠ»Π½ΠΎΡΡ | -115,83 | -5,52% |
ΠΠ°ΡΠ°Π΄Π° ΠΏΠΎ Π°ΠΊΡΠΈΡΠΈ | β | β |
EBITDA | -1,35Β ΠΌΠΈΠ». | 12,08% |
ΠΡΠ΅ΠΊΡΠΈΠ²Π½Π° ΠΏΠΎΡΠ΅ΡΠΊΠ° ΡΡΠΎΠΏΠ° | -1,21% | β |
ΠΠΈΠ»Π°Π½Ρ ΡΡΠ°ΡΠ°
Π£ΠΊΡΠΏΠ½Π° Π°ΠΊΡΠΈΠ²Π°
Π£ΠΊΡΠΏΠ½Π΅ ΠΎΠ±Π°Π²Π΅Π·Π΅
| (EUR) | ΡΡΠ½ 2025.info | ΠΡΠΎΠΌΠ΅Π½Π° Π/Π |
|---|---|---|
ΠΠΎΡΠΎΠ²ΠΈΠ½Π° ΠΈ ΠΊΡΠ°ΡΠΊ. ΡΠ»Π°Π³Π°ΡΠ° | 663,00Β Ρ ΠΈΡ. | -82,63% |
Π£ΠΊΡΠΏΠ½Π° Π°ΠΊΡΠΈΠ²Π° | 12,66Β ΠΌΠΈΠ». | -30,23% |
Π£ΠΊΡΠΏΠ½Π΅ ΠΎΠ±Π°Π²Π΅Π·Π΅ | 42,08Β ΠΌΠΈΠ». | 9,33% |
Π£ΠΊΡΠΏΠ½Π° Π²ΡΠ΅Π΄Π½ΠΎΡΡ Π°ΠΊΡΠΈΡΠ° | -29,42Β ΠΌΠΈΠ». | β |
ΠΠ΅ΠΈΡΠΏΠ»Π°ΡΠ΅Π½Π΅ Π°ΠΊΡΠΈΡΠ΅ | 79,74Β ΠΌΠΈΠ». | β |
Π’ΡΠΆΠΈΡΠ½Π° ΠΏΡΠ΅ΠΌΠ° Π½ΠΎΠΌΠΈΠ½Π°Π»Π½ΠΎΡ | -0,49 | β |
ΠΠΎΠ²ΡΠ°ΡΠ°Ρ Π°ΠΊΡΠΈΠ²Π΅ | -27,57% | β |
ΠΠΎΠ²ΡΠ°ΡΠ°Ρ ΠΊΠ°ΠΏΠΈΡΠ°Π»Π° | -101,28% | β |
Π’ΠΎΠΊ Π½ΠΎΠ²ΡΠ°
ΠΠ΅ΡΠΎ ΠΏΡΠΎΠΌΠ΅Π½Π° Ρ Π½ΠΎΠ²ΡΡ
| (EUR) | ΡΡΠ½ 2025.info | ΠΡΠΎΠΌΠ΅Π½Π° Π/Π |
|---|---|---|
ΠΠ΅ΡΠΎ ΠΏΡΠΈΡ
ΠΎΠ΄ | -2,33Β ΠΌΠΈΠ». | 0,36% |
ΠΠΎΡΠΎΠ²ΠΈΠ½Π° ΠΈΠ· ΠΏΠΎΡΠ»ΠΎΠ²Π°ΡΠ° | -1,10Β ΠΌΠΈΠ». | 41,90% |
ΠΠΎΡΠΎΠ²ΠΈΠ½Π° ΠΈΠ· ΠΈΠ½Π²Π΅ΡΡΠΈΡΠ°ΡΠ° | 116,00Β Ρ ΠΈΡ. | 217,81% |
ΠΠΎΡΠΎΠ²ΠΈΠ½Π° ΠΈΠ· ΡΠΈΠ½Π°Π½ΡΠΈΡΠ°ΡΠ° | 336,50Β Ρ ΠΈΡ. | 248,57% |
ΠΠ΅ΡΠΎ ΠΏΡΠΎΠΌΠ΅Π½Π° Ρ Π½ΠΎΠ²ΡΡ | -677,00Β Ρ ΠΈΡ. | 67,54% |
Π‘Π»ΠΎΠ±ΠΎΠ΄Π°Π½ ΡΠΎΠΊ Π½ΠΎΠ²ΡΠ° | -460,56Β Ρ ΠΈΡ. | 43,00% |
ΠΡΠ½ΠΎΠ²Π½ΠΈ ΠΏΠΎΠ΄Π°ΡΠΈ
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
ΠΠ·Π²ΡΡΠ½ΠΈ Π΄ΠΈΡΠ΅ΠΊΡΠΎΡ: CEO
ΠΠ°ΡΡΠΌ ΠΎΡΠ½ΠΈΠ²Π°ΡΠ°
2000
ΠΠ΅Π±-ΡΠ°ΡΡ
ΠΡΠΎΡ Π·Π°ΠΏΠΎΡΠ»Π΅Π½ΠΈΡ
61